TY - JOUR
T1 - Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution
AU - Fisher, Rosalie
AU - Horswell, Stuart
AU - Rowan, Andrew
AU - Salm, Maximilian P.
AU - de Bruin, Elza C.
AU - Gulati, Sakshi
AU - McGranahan, Nicholas
AU - Stares, Mark
AU - Gerlinger, Marco
AU - Varela, Ignacio
AU - Crockford, Andrew
AU - Favero, Francesco
AU - Quidville, Virginie
AU - André, Fabrice
AU - Navas, Carolina
AU - Grönroos, Eva
AU - Nicol, David
AU - Hazell, Steve
AU - Hrouda, David
AU - O'Brien, Tim
AU - Matthews, Nik
AU - Phillimore, Ben
AU - Begum, Sharmin
AU - Rabinowitz, Adam
AU - Biggs, Jennifer
AU - Bates, Paul A.
AU - McDonald, Neil Q.
AU - Stamp, Gordon
AU - Spencer-Dene, Bradley
AU - Hsieh, James J.
AU - Xu, Jianing
AU - Pickering, Lisa
AU - Gore, Martin
AU - Larkin, James
AU - Swanton, Charles
N1 - Funding Information:
We thank the patients and acknowledge the assistance of the FACS laboratory at CRUK London Research Institute and the Beijing Genomics Institute. The results published here are in part based upon data generated by TCGA pilot project established by the NCI and NHGRI. Information about TCGA and the investigators and institutions who constitute the TCGA research network can be found at http://cancergenome.nih.gov/. RF and JL received funding from EU FP7 (PREDICT project), EB is a Rosetrees Trust fellow, NM received funding from the Rosetrees Trust, MG is funded by the UK Medical Research Council, IV is funded by Spanish Ministerio de Economía y Competitividad subprograma Ramón y Cajal, and CS is a senior Cancer Research UK clinical research fellow and is funded by Cancer Research UK, the Rosetrees Trust, EU FP7 (projects PREDICT and RESPONSIFY, ID:259303), the Prostate Cancer Foundation, and the Breast Cancer Research Foundation. This study was supported by researchers at the National Institute for Health Research Biomedical Research Centres at University College London Hospitals and at the Royal Marsden Hospital.
PY - 2014/1/1
Y1 - 2014/1/1
N2 - BACKGROUND: Genomic analysis of multi-focal renal cell carcinomas from an individual with a germline VHL mutation offers a unique opportunity to study tumor evolution.RESULTS: We perform whole exome sequencing on four clear cell renal cell carcinomas removed from both kidneys of a patient with a germline VHL mutation. We report that tumors arising in this context are clonally independent and harbour distinct secondary events exemplified by loss of chromosome 3p, despite an identical genetic background and tissue microenvironment. We propose that divergent mutational and copy number anomalies are contingent upon the nature of 3p loss of heterozygosity occurring early in tumorigenesis. However, despite distinct 3p events, genomic, proteomic and immunohistochemical analyses reveal evidence for convergence upon the PI3K-AKT-mTOR signaling pathway. Four germline tumors in this young patient, and in a second, older patient with VHL syndrome demonstrate minimal intra-tumor heterogeneity and mutational burden, and evaluable tumors appear to follow a linear evolutionary route, compared to tumors from patients with sporadic clear cell renal cell carcinoma.CONCLUSIONS: In tumors developing from a germline VHL mutation, the evolutionary principles of contingency and convergence in tumor development are complementary. In this small set of patients with early stage VHL-associated tumors, there is reduced mutation burden and limited evidence of intra-tumor heterogeneity.
AB - BACKGROUND: Genomic analysis of multi-focal renal cell carcinomas from an individual with a germline VHL mutation offers a unique opportunity to study tumor evolution.RESULTS: We perform whole exome sequencing on four clear cell renal cell carcinomas removed from both kidneys of a patient with a germline VHL mutation. We report that tumors arising in this context are clonally independent and harbour distinct secondary events exemplified by loss of chromosome 3p, despite an identical genetic background and tissue microenvironment. We propose that divergent mutational and copy number anomalies are contingent upon the nature of 3p loss of heterozygosity occurring early in tumorigenesis. However, despite distinct 3p events, genomic, proteomic and immunohistochemical analyses reveal evidence for convergence upon the PI3K-AKT-mTOR signaling pathway. Four germline tumors in this young patient, and in a second, older patient with VHL syndrome demonstrate minimal intra-tumor heterogeneity and mutational burden, and evaluable tumors appear to follow a linear evolutionary route, compared to tumors from patients with sporadic clear cell renal cell carcinoma.CONCLUSIONS: In tumors developing from a germline VHL mutation, the evolutionary principles of contingency and convergence in tumor development are complementary. In this small set of patients with early stage VHL-associated tumors, there is reduced mutation burden and limited evidence of intra-tumor heterogeneity.
UR - http://www.scopus.com/inward/record.url?scp=84964314111&partnerID=8YFLogxK
U2 - 10.1186/s13059-014-0433-z
DO - 10.1186/s13059-014-0433-z
M3 - Article
C2 - 25159823
AN - SCOPUS:84964314111
SN - 1474-7596
VL - 15
SP - 433
JO - Genome biology
JF - Genome biology
IS - 8
M1 - 433
ER -